18 May 2022 , 07:54 AM
Net profit of Sharon Bio-Medicine declined 16.58% to Rs 4.68 crore in the quarter ended March 2022 as against Rs 5.61 crore during the previous quarter ended March 2021. Sales rose 8.16% to Rs 48.53 crore in the quarter ended March 2022 as against Rs 44.87 crore during the previous quarter ended March 2021. For the full year,net profit rose 25.77% to Rs 17.67 crore in the year ended March 2022 as against Rs 14.05 crore during the previous year ended March 2021. Sales rose 11.92% to Rs 184.53 crore in the year ended March 2022 as against Rs 164.88 crore during the previous year ended March 2021.
| Particulars | Quarter Ended | Year Ended | ||||
| ? | Mar. 2022 | Mar. 2021 | % Var. | Mar. 2022 | Mar. 2021 | % Var. |
| Sales | 48.53 | 44.87 | 8 | 184.53 | 164.88 | 12 |
| OPM % | 13.13 | 14.40 | – | 14.20 | 13.11 | – |
| PBDT | 7.48 | 8.50 | -12 | 28.90 | 25.56 | 13 |
| PBT | 4.68 | 5.61 | -17 | 17.67 | 14.05 | 26 |
| NP | 4.68 | 5.61 | -17 | 17.67 | 14.05 | 26 |
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
